Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC]
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Multiclonal Interferon regulatory factor 9/IRF-9 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human IRF9 aa 150-250.
View Alternative Names
ISGF3G, IRF9, Interferon regulatory factor 9, IRF-9, IFN-alpha-responsive transcription factor subunit, ISGF3 p48 subunit, Interferon-stimulated gene factor 3 gamma, Transcriptional regulator ISGF3 subunit gamma, ISGF-3 gamma
- ICC
Supplier Data
Immunocytochemistry - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (AB277803)
Immunofluorescence was performed on fixed and permeabilized Jurkat cells for detection of endogenous IRF9 using Anti-IRF9 Recombinant Rabbit Polyclonal Antibody (ab277803, 2 μg/mL) and labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (1/2000). Panel a) shows representative cells that were stained for detection and localization of IRF9 protein (green), Panel b) is stained for nuclei (blue) using SlowFade® Gold Antifade Mountant with DAPI. Panel c) represents cytoskeletal F-actin staining using Alexa Fluor® 555 Rhodamine Phalloidin (1/300). Panel d) is a composite image of Panels a, b and c clearly demonstrating cytoplasmic localization of IRF9. Panel e) represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.
- WB
Supplier Data
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (AB277803)
Western blot analysis was performed on whole cell extracts (30 μg lysate) of Jurkat (human T cell leukemia cell line from peripheral blood) (Lane 1), Jurkat treated with IFN-alpha (10 ng/mL for 16hr) (Lane 2), MCF7 (human breast adenocarcinoma cell line) (Lane 3), MCF7 treated with IFN-alpha (10 ng/mL for 16hr) (Lane 4), PC3 (human prostate adenocarcinoma cell line) (Lane 5) and PC3 treated with IFN-alpha (10 ng/mL for 16hr) (Lane 6).
The blots were probed with ab277803 at 1-2 μg/mL and detected by chemiluminescence using a Goat anti-Rabbit IgG (H+L)-HRP secondary antibody, (0.4 μg/mL, 1/2500 dilution).
4-12% Bis-Tris gel.
The membrane was probed with the relevant primary and secondary antibody following blocking with 5% skimmed milk. Chemiluminescent detection was performed.
All lanes:
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (ab277803)
Predicted band size: 44 kDa
false
- WB
Lab
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (AB277803)
False colour image of Western blot : Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] staining at 2 μg/ml, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab277803 was shown to bind specifically to Interferon regulatory factor 9/IRF-9. A band was observed at 48 kDa in treated wild-type A549 cell lysates with no signal observed at this size in IRF9 knockout cell line ab267119 (knockout cell lysate ab258473). To generate this image, wild-type and IRF9 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
All lanes:
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (ab277803) at 2 µg/mL
Lane 1:
Wild-type A549 treated IFNg (10 IU/ml, 24 h) cell lysate at 20 µg
Lane 2:
IRF9 knockout A549 treated IFNg (10 IU/ml, 24 h) cell lysate at 20 µg
Lane 3:
Wild-type A549 vehicle control IFNg (0 IU/ml, 24 h) cell lysate at 20 µg
Lane 4:
IRF9 knockout A549 vehicle control IFNg (0 IU/ml, 24 h) cell lysate at 20 µg
Predicted band size: 44 kDa
Observed band size: 48 kDa
false
- WB
Lab
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (AB277803)
False colour image of Western blot : Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] staining at 2 μg/ml, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab277803 was shown to bind specifically to Interferon regulatory factor 9/IRF-9. A band was observed at 48 kDa in treated wild-type HeLa cell lysates with no signal observed at this size in IRF9 knockout cell line ab266051 (knockout cell lysate ab258472). The band observed in the knockout lysate lane below 48 kDa is likely to represent a truncated form of Interferon regulatory factor 9/IRF-9. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and IRF9 knockout HeLa cell lysates were analysed.First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
All lanes:
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (ab277803) at 1/1000 dilution
Lane 1:
Wild-type HeLa treated hIFN-a1 (10 ng/ml, 16 h) cell lysate at 20 µg
Lane 2:
IRF9 knockout HeLa treated hIFN-a1 (10 ng/ml, 16 h) cell lysate at 20 µg
Lane 3:
Wild-type HeLa vehicle control hIFN-a1 (0 ng/ml, 16 h) cell lysate at 20 µg
Lane 4:
IRF9 knockout HeLa vehicle control hIFN-a1 (0 ng/ml, 16 h) cell lysate at 20 µg
Predicted band size: 44 kDa
Observed band size: 48 kDa
false
- WB
Lab
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (AB277803)
False colour image of Western blot : Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] staining at 2 μg/ml, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab277803 was shown to bind specifically to Interferon regulatory factor 9/IRF-9. A band was observed at 48 kDa in treated wild-type HeLa cell lysates with no signal observed at this size in IRF9 CRISPR-Cas9 edited cell line ab266051 (CRISPR-Cas9 edited cell lysate ab258472). The band observed in the CRISPR-Cas9 edited lysate lane below 48 kDa is likely to represent a truncated form of Interferon regulatory factor 9/IRF-9. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and IRF9 CRISPR-Cas9 edited HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
All lanes:
Western blot - Anti-Interferon regulatory factor 9/IRF-9 antibody [14HCLC] (ab277803) at 2 µg/mL
Lane 1:
Wild-type HeLa treated hIFN-a1 (10 ng/ml, 16 h) cell lysate at 20 µg
Lane 2:
IRF9 knockout HeLa treated hIFN-a1 (10 ng/ml, 16 h) cell lysate at 20 µg
Lane 2:
Western blot - Human IRF9 (Interferon regulatory factor 9) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-irf9-interferon-regulatory-factor-9-knockout-hela-cell-line-ab266051'>ab266051</a>)
Lane 3:
Wild-type HeLa vehicle control hIFN-a1 (0 ng/ml, 16 h) cell lysate at 20 µg
Lane 4:
IRF9 knockout HeLa vehicle control hIFN-a1 (0 ng/ml, 16 h) cell lysate at 20 µg
Predicted band size: 44 kDa
Observed band size: 48 kDa
false
Reactivity data
Product details
What are recombinant multiclonals?
Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:
- - The sensitivity of polyclonal antibodies by recognising multiple epitopes
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
View our range of recombinant multiclonal antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF-9 participates in the assembly of the transcription factor complex ISGF3 alongside STAT1 and STAT2. This complex translocates into the nucleus to initiate the transcription of interferon-stimulated genes that promote antiviral states. IRF-9 through this functional role impacts a range of cellular responses including proliferation apoptosis and immune regulation. It affects the temporal and spatial aspects of gene expression in response to interferons.
Pathways
IRF-9 plays a significant role in both the Jak-STAT and interferon signaling pathways. These pathways are essential for the activation of genes involved in immune defense. Through its involvement in these pathways IRF-9 interacts with proteins such as STAT1 and STAT2 creating a bridge between extracellular signals and gene activation. This involvement ensures that cells can respond effectively to viral infections enhancing innate and adaptive immune responses.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Communications biology 8:1209 PubMed40804340
2025
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com